We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Siegfried Holding AG (SFZN) CHF21.2

Sell:1,124.00 CHF Buy:1,138.00 CHF Change: 14.00 CHF (1.23%)
Market closed |  Prices as at close on 5 November 2024 | Switch to live prices |
Sell:1,124.00 CHF
Buy:1,138.00 CHF
Change: 14.00 CHF (1.23%)
Market closed |  Prices as at close on 5 November 2024 | Switch to live prices |
Sell:1,124.00 CHF
Buy:1,138.00 CHF
Change: 14.00 CHF (1.23%)
Market closed |  Prices as at close on 5 November 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.

Contact details

Address:
Untere Bruehlstrasse 4
ZOFINGEN
4800
Switzerland
Telephone:
+41 (62) 7461111
Website:
https://www.siegfried.ch/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SFZN
ISIN:
CH0014284498
Market cap:
5.14 billion CHF
Shares in issue:
4.29 million
Sector:
Life Sciences Tools & Services
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Reto Suter
    Interim Chief Executive Officer, Chief Financial Officer, Member of the Executive Committee
  • Irene Wosgien
    Chief Human Resource Officer
  • Juergen Roos
    Chief Scientific Officer, Member of the Executive Committee
  • Christian Dowdeswell
    Chief Business Officer Drug Substances, Member of the Executive Committee
  • Marcel Imwinkelried
    Chief Operating Officer Drug Products, Member of the Executive Committee
  • Henrik Krupper
    Chief Operating Officer Drug Substances, Member of the Executive Committee
  • Marianne Spaene
    Chief Business Officer, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.